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Abstract 
Background: There is a concerted push for adopting a minimalist strategy with emphasis 
on early hospital discharge for patients undergoing Transcatheter aortic valve implantation 
(TAVI). However, studies on discharge patterns and predictors of early discharge (≤3 days 
post-TAVI) are sparse, in the United States.      
Methods: We analyzed using Healthcare Utilization Project, Nationwide inpatient Sample 
database, 2011-2012. A total of 7,321 TAVI procedures were identified. We compared in-
hospital outcomes between early and late discharge cohorts, and determined the predictors 
of early discharge. Correlation of costs and post-TAVI length of stay was also performed.    
Results: Early discharge rate post-TAVI was about 21% in the United States, in 2011-
2012. Overall mean age was 81 years. In-hospital adverse outcomes post-TAVI were 
higher in late discharge cohort (p<0.001). Mean length of stay post-TAVI (7.7 days vs. 2.6 
days) and costs ($208,752 vs. $157,663) were significantly higher in late discharge than 
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early discharge cohort. Females, bleeding, blood transfusions, stroke, permanent 
pacemakers, mechanical circulatory support, acute kidney injury were associated with 
significantly lower adjusted odds for early discharge. Transfemoral TAVI approach, prior 
aortic valvuloplasty, and procedure year 2012 were associated with significantly higher 
odds for early discharge. We observed positive correlation between costs of hospitalization 
and post-TAVI length of stay (R=0.58; p<0.001).  
Conclusions: Females, bleeding, blood transfusions, stroke, permanent pacemakers, 
mechanical circulatory support devices, renal failure were associated with lower odds for 
early discharge. Transfemoral approach and prior aortic valvuloplasty increased the 
likelihood for early discharge. Post-TAVI length of stay was associated with significantly 
higher hospitalization costs.     
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Introduction 
Severe aortic stenosis (AS) is a leading cause of morbidity and mortality in the elderly 
adults.1 Transcatheter aortic valve implantation (TAVI) has emerged as a promising 
therapeutic intervention in patients with prohibitive-, high- and intermediate-risk for 
surgical aortic valve replacement for severe AS.2-4  
In the current era of cost containment, there is a concerted push for adopting a 
minimalist strategy in the TAVI patient population periprocedurally.5 Constituent 
components of minimalist strategy generally include the following: preference for 
conscious sedation; transfemoral access; limiting the utility of transeophageal 
echocardiogram intraprocedurally; and early hospital discharge.5  
Traditionally, a significant number of patients are kept in the hospital for prolonged 
monitoring ostensibly more from an abundance of caution than  for valid clinical reasons,  
thus adding significantly to the costs of hospitalization.6 Recent European studies have 
demonstrated the feasibility and safety of early hospital discharge after transfemoral 
TAVI.6,7 Understanding existing nationwide discharge patterns post-TAVI is critical in 
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order to improve early hospital discharge percentage. However, systematic studies on 
discharge trends post TAVI are lacking in the United States. 
The primary objective of our study was to identify predictors of early hospital 
discharge. Secondary objectives were: 1) Compare in-hospital outcomes and healthcare 
resource utilization in early vs. late discharge cohorts; 2) Ascertain the relationship 
between costs of hospitalization and length of stay, in TAVI.  
 
Methods 
Data Source 
Our analysis was performed using Healthcare Utilization Project’s (HCUP) Nationwide 
Inpatient Sample (NIS) database, which is sponsored by the Agency for Healthcare 
Research and Quality (AHRQ).  NIS is the largest all-payer inpatient care database 
available to public that represents 20% sample of all nonfederal community hospitals in 
the United States.8 Weights provided by AHRQ were utilized generate national estimates 
representing >95% of hospital discharges.9 It contains deidentified extensive data on 
demographics, clinical information, procedures performed, costs etc, for each 
hospitalization.    
Study Population 
We retrieved a total of 7,560 hospitalizations with the principal procedure of TAVI using 
Internal Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
codes (35.05 for transfemoral TAVI; 35.06 for transapical TAVI). About 239 subjects had 
missing values for day of length of inhospital stay and hence were excluded. Patients who 
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suffered in-hospital death were not included this analysis considering our study objectives. 
Our final cohort comprised of 7,321 procedures.  
Outcomes    
Similar to prior studies, 6,7 we defined “early discharge” as day of discharge ≤3 days post-
TAVI and “late discharge” as day of discharge >3 days post-TAVI. We compared in-
hospital outcomes related to TAVI, such as postoperative bleeding, blood transfusions, 
stroke or transient ischemic attacks (TIA), acute kidney injury (AKI), use of mechanical 
circulatory support, permanent pacemakers, valvuloplasty, length of hospitalization and 
costs between early discharge and late discharge cohorts. ICD-9-CM codes were utilized 
to determine these outcomes (Supplementary Table). Multivariate models were created to 
identify various factors and outcomes associated with early discharge. Association of 
hospitalization costs (estimate of charges billed by the hospital) and post-TAVI length of 
stay was also analyzed. Elixhauser comorbidity core was used to measure severity of 
comorbidity burden.10 NIS database contains completely de-identified data, which 
precludes need for institutional review board approval.     
Statistical Analysis 
We used trend weights provided by the HCUP NIS to generate national estimates including 
sum, rates, mean, proportion and their standard error. To compare baseline characteristics 
between patients with early discharge to those with late discharge, we use chi-square test 
for categorical variable and t-test/Wilcoxon rank sum test for continuous variable (as 
appropriate). Mixed effect logistic model was utilized to assess for independent predictors 
of early discharge in patients after TAVI, given the nested observations in the NIS 
database. This model enables us to account for the potential correlation of observations 
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within each hospital. As patient factors are nested within hospital level factors, we build a 
hierarchical model with unique hospital identification number as random effects in the 
model.  
      A multivariate model was created using all the significant variables based on 
initial univariate analysis. Gender, postoperative bleeding, blood transfusion, stroke/TIA, 
AKI, pacemakers, mechanical circulatory support use, year of procedure, prior aortic 
valvuloplasty, TAVI approach (transfemoral vs. transapical) were included in the final 
multivariate model after adjusting for various patient- and hospital-level factors (age, race, 
Elixhauser comorbidity score, hospital region, bed size, primary expected payer, median 
household income). Data was complete for all variables except race (6.3%) and median 
income (1.3%). We therefore performed multiple imputations using the chained equation 
procedure in STATA to account for the missing data. Correlation between hospitalization 
costs and the length of stay post-TAVI was evaluated via Pearson correlation coefficient. 
We analyzed using STATA 14 (StataCorp, College Station, TX) and SPSS Statistics 23 
(IBM Corp., Armonk, NY); 2-tailed α=0.05.  
 
Results 
Baseline Characteristics (Table 1) 
Early discharge and late discharge cohorts consisted of 1,557 and 5,764 procedures 
respectively. Mean age of overall cohort was 81 years. Study comprised of 48% females 
and 84.5% Whites. Elixhauser comorbidity score was lower in early discharge cohort (2.8 
vs. 3.2). Approximately 85% of procedures were in 2012 and 83% were via transfemoral 
approach.   
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In-hospital Outcomes  
Approximately 21% of patients were discharged in ≤3 days after TAVI. Figure 1 depicts 
distribution of patients according to day of discharge post-TAVI in the entire cohort.  
Among early discharge cohort, approximately 85% were discharged home, but among late 
discharge cohort; about 40% were discharged to extended care facilities/nursing homes 
(Figure 2). Early discharge rates improved from 11% in 2011 to 22% in 2012 (Figure 3). 
Only 5% of patients who underwent transapical TAVI were discharged early as opposed 
to 25% among transfemoral cohort (Figure 4). TAVI related complications such as 
postoperative bleeding, stroke or TIA, need for blood transfusions, AKI, use of mechanical 
circulatory support (intra-aortic balloon pump, extracorporeal membrane oxygenation, 
Impella, Tandem Heart, cardiopulmonary bypass), new permanent pacemaker implants 
were significantly higher in late discharge cohort (Table 2). However,  pre-TAVI aortic 
valvuloplasty was performed more often in early discharge cohort. Mean length of stay 
post-TAVI (7.7 days vs. 2.6 days) and total hospital charges ($208,752 vs. $157,663) were 
significantly higher in late discharge than early discharge cohort (Table 2).     
Predictors of Early Discharge (Table 3) 
Multivariate predictors that were significantly associated with lower likelihood for early 
discharge were: females (adjusted OR: 0.61; 95%CI: 0.44-0.83; p=0.002), postoperative 
bleeding (adjusted OR: 0.36; 95%CI: 0.18-0.72; p=0.004), blood transfusion (adjusted OR: 
0.29; 95%CI: 0.19-0.46; p<0.001), stroke or TIA (adjusted OR: 0.13; 95%CI: 0.02-0.94; 
p=0.04), AKI (adjusted OR: 0.59; 95%CI: 0.38-0.96; p=0.04), permanent pacemakers 
(adjusted OR: 0.18; 95%CI: 0.08-0.40; p<0.001), and mechanical circulatory support use 
(adjusted OR: 0.31; 95%CI: 0.13-0.75; p=0.009). Year of TAVI (adjusted OR: 1.37; 
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95%CI: 1.12-1.67; p=0.002), transfemoral approach (adjusted OR: 4.80; 95%CI: 2.51-
9.17; p<0.001) prior aortic valvuloplasty (adjusted OR: 2.40; 95%CI: 1.00-5.87; p=0.04) 
were associated with higher odds for early discharge.  
 
Correlation of hospitalization costs and post-TAVI length of stay 
Figure 5 demonstrates direct and positive correlation between costs of hospitalization and 
length of inpatient stay after TAVI (R=0.58; p<0.001).  
 
Discussion 
Early discharge was observed in 21% of patients after TAVI in the United States between 
2011-2012. Early discharge cohort had significantly lower rates of adverse in-hospital 
outcomes, mechanical circulatory support use, and permanent pacemaker implantation in 
comparison to the late discharge cohort.  Females, postoperative bleeding, blood 
transfusion, AKI, stroke or TIA, permanent pacemaker implantation, mechanical 
circulatory support use were significantly associated with lower adjusted odds of early 
discharge post-TAVI. However, prior aortic valvuloplasty, transfemoral TAVI approach, 
year of procedure were significantly associated with higher adjusted odds of early 
discharge. Lastly, we observed a strong positive correlation between costs of 
hospitalization and length of stay after TAVI. 
At 30-days follow-up, bleeding complications were seen in 22.5% patients after 
TAVI in PARTNER trial.11 However, postoperative bleeding rate during index 
hospitalization was much lower at 9.2% in our study. The stark difference in rate of 
bleeding complications is probably due to longer period of follow-up in former study. In 
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addition, we noted significant association of postoperative bleeding with lower odds of 
early discharge consistent with prior reports.6,7 Bleeding events requiring transfusions were  
3-fold higher in the late discharge cohort and a strong predictor of lower early discharge 
rates in our study, congruent with prior work.7,12 Similarly, AKI was noted more commonly 
in late discharge cohort and likewise strongly associated with lower likelihood of early 
discharge in this study. Blood transfusions are predictive of AKI and the incidence of which 
is estimated to be around 12% post-TAVI.13 Bleeding events,12 AKI,13 and blood 
transfusions12 also predict mortality post-TAVI. Avoiding vascular complications, 
judicious use of radiocontrast dye and avoiding prolonged intraprocedural hypotension can 
potentially curtail these adverse outcomes.   
Stroke after TAVI is a strong predictor of mortality.14 Similar to prior studies,6,7,15 
we noted stroke/TIA in 2.8% patients, significant proportion of which had prolonged 
hospitalization. Post-TAVI stroke was associated with significantly lower odds for early 
discharge in contrast to a prior analysis.6 Over the years, incidence of stroke post-TAVI 
has declined owing to technological adv ncements valve deployment, experience, and case 
selection but opportunities for improvement remain.5,14       
We found female gender to be significantly associated with lower likelihood for 
early discharge in a multivariate model, unlike a previous Italian study.6 A recent study on 
all-female international TAVI registry16 reported a low incidence of early mortality and 
stroke, yet mean length of stay was 12 days.  
Mechanical circulatory support use in TAVI was noted in 10.6% of cases in a recent 
study on the same database.17 Slightly lower utilization rate of 8.6% in current study may 
be ascribed to the  exclusion of subjects with in-hospital mortality. Expectedly in this study, 
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subjects who required mechanical circulatory support during TAVI were less likely to be 
discharged early. In addition, its use has been reported to predict higher mortality, length 
of stay and costs.17   
Permanent pacemakers were implanted in approximately 10% of our cohort post-
TAVI, in contrast to 5.9% and 16% in previous studies.6,7 Varied utility of balloon-
expandable valve vs. self-expandable valve in these studies explains the difference in 
pacemaker requirements as the latter valve is associated with significantly higher 
conduction blocks due to mechanical impingement.5-7 Permanent pacemaker implantation 
post-TAVI was significantly associated with lower rates of early discharge in current study; 
in contrast, the presence of a preexisting permanent pacemakers predicted higher rates of 
early discharge.6,7 Occurrence of advanced conduction blocks post-TAVI typically  
involves prolonged monitoring before permanent pacemaker implants are considered.  
Balloon aortic valvuloplasty performed prior to TAVI was associated with higher 
likelihood for early discharge. Aortic valvuloplasty prior to TAVI is thought to faciliate 
optimal sizing and smooth deployment of transcatheter valves potentially reducing 
paravalvular leaks.5,18 However, a recent large meta-analysis involving 1,395 patients 
showed no significant difference clinical outcomes if TAVI is performed with or without 
prior valvuloplasty.18 Patients who underwent TAVI more recently fared better in terms 
clinical outcomes as well as early discharge rates.5,6 Similarly, TAVI in 2012 was 
significantly associated with early discharge as compared to 2011, likely owing to operator 
learning curves. Transfemoral TAVI was associated with higher rates of early discharge 
when compared to transapical approach. Our results are consistent with PARTNER trial,19 
in whom mean post-procedural length of stay after transfemoral approach was 
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approximately 7 days while it was 12 days after a transapical approach. Additionally, 
transfemoral TAVI is associated with significant reduction in costs of hospitalization,5,19 
and the costs are even lower with a minimalist approach.20  
Systematic studies and guidelines on ideal duration of post-TAVI monitoring are 
lacking.7 Mean duration of hospitalization post-TAVI was three times longer in late 
discharge cohort in comparison to early discharge cohort in this study. Our results were 
comparable to prior work by Barbanti et al.6 Early discharge rates improved from 5.6% to 
50% from 2007 to 2014 in the same study.6 With adoption of a minimalist approach for 
TAVI, early discharge rates are likely to improve significantly,5 especially because there 
was no significant difference in adverse outcomes observed between early and late 
discharge cohorts at 30-days follow-up.6,7 Increasing hospital volume has been tied to early 
discharge in an earlier study on same database.21 Home discharge and nursing home 
discharge rates post-TAVI are significantly higher for early discharge and late discharge 
cohorts respectively. 
Furthermore, financial implications of late discharge cannot be underestimated.19,20 
Total hospitalization costs were higher by one-third, in the late discharge cohort as found 
in our study. We also demonstrated significant positive correlation between costs of 
hospitalization and post-TAVI length of stay (Figure 5). Avoiding unnecessary procedures 
and routine transfer to intensive care units for post-procedural monitoring, mitigating 
procedural complications,22 universal adoption of minimalist approach unless 
inappropriate, conscious effort to discharge early if clinically stable can potentially curtail 
excessive healthcare costs involved.5-7,19,20  
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved 
We would like to point out few limitations of our study. Considering the 
administrative nature of the NIS database, it is subject to coding limitations as we used 
ICD-9-CM codes to retrieve study subjects and outcomes. However, similar methods have 
been used extensively in prior studies.17,21 Overall rate of in-hospital outcomes and 
healthcare resource utilization should be interpreted with caution as we deliberately 
excluded patients who did not survive to hospital discharge. NIS database lacks 
information on type of transcatheter valve, surgical risk score, echocardiographic variables, 
degree of paravalvular leak post-TAVI, and post-discharge follow-up data, although no 
significant difference in clinical outcomes were noted in early discharge group at follow-
up.6,7 Both balloon expandable and self expandable types of transcatheter aortic valves 
were included in our study.21 Despite these limitations, our study depicts nationally 
representative real-world patient data, which is largest of its kind to date, analyzing early 
experience of discharge patterns in the United States. While contemporary data would 
probably show improvements in length of stay, predictors of prolonged hospitalization 
post-TAVI observed in our study are likely to still be relevant. The ongoing multimodality, 
multidisciplinary but minimalist approach (3M) to transfemoral TAVI, a prospective study 
(clinical trial NCT02287662), that aims to analyze feasibility and safety of early discharge 
with adoption of Vancouver TAVI clinical pathway23 could give more definitive answers.  
 
Conclusions 
 Females, postoperative bleeding, blood transfusions, stroke, AKI, permanent pacemaker 
implantation, use of mechanical circulatory support were factors less likely to be associated 
with early discharge, whereas transfemoral approach, year of procedure and prior aortic 
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valvuloplasty were more likely to be associated with early discharge after TAVI. There 
was a strong and positive correlation between post-TAVI length of stay and hospitalization 
costs.        
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Figure Legends:  
 
 
Figure 1: Bar diagram of day of discharge after TAVI in entire cohort  
 
 
Figure 2: Bar diagram of discharge destination stratified according to discharge timing 
 
 
Figure 3: Bar diagram of discharge timing stratified according to year of procedure 
 
 
Figure 4: Bar diagram of discharge timing stratified according to TAVI approach 
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Figure 5: Scatter plot diagram of costs of hospitalization vs. length of stay (day of 
discharge) after TAVI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Baseline Characteristics 
Variables Early Discharge Cohort Late Discharge Cohort Overall P Value 
Total number of 
procedures 
1,557 5,764 7,321  
Age, mean 80.9+0.24 81.2+0.11 81.1+0.10 0.298 
Female, % 38.8 50.6 48.1 <0.001 
Race, %    <0.001 
White 83.2 84.8 84.5  
Black 6.1 3.3 3.9  
Hispanics 3.4 2.9 3.0  
Median household 
income national quartile 
for patient’s ZIP code, 
Percentile 
   <0.001 
0-25th 20.4 22.0 21.6  
26th-50th 23.7 21.7 22.1  
51st-75th  30.3 25.1 26.2  
76th-100th 25.7 31.2 30.0  
Primary expected payer, 
%    
<0.001 
Medicare 87.2 90.9 90.1  
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Medicaid 0.6 1.2 1.1  
Private insurance 10.3 6.4 7.3  
No insurance 0.6 0.4 0.5  
Elixhauser comorbidity 
score (mean,+SE) 
2.8+0.03 3.2+0.02 3.1+0.18 <0.001 
Year of procedure    <0.001 
2011 9.1 16.5 14.9  
2012 90.9 83.5 85.1  
TAVI approach     <0.001 
Transfemoral 95.3 80.0 83.3  
Transapical 4.7 20.0 16.7  
Hospital Characteristics     
Hospital bed size, %    <0.001 
Small 5.5 1.0 1.9  
Medium 15.8 12.1 12.9  
Large 78.7 86.9 85.2  
Hospital region, %    <0.001 
Northeast 20.7 30.9 28.7  
Midwest 25.6 23.5 23.9  
South 39.8 37.0 37.6  
West 13.9 8.7 9.8  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved 
 
 
 
 
 
 
 
 
 
Table 2: In-hospital Outcomes and Healthcare Resources Utilization 
 
Outcomes Early Discharge Cohort Late Discharge Cohort Overall P Value 
Postoperative 
bleeding, % 
4.8 10.4 9.2 <0.001 
Blood transfusion, % 11.2 33.4 28.7 <0.001 
Stroke/TIA, % 0.3 3.5 2.8 <0.001 
AKI, % 6.5 18.2 15.7 <0.001 
Any mechanical 
circulatory support, 
%  
2.9 10.2 8.6 <0.001 
Intra-aortic balloon 
pump, % 
0.3 1.4 1.2 <0.001 
ECMO, % 0.0 0.2 0.1 0.100 
Impella/Tandem 
Heart, % 
0.3 0.2 0.3 0.591 
Cardiopulmonary 
bypass, % 
2.3 8.7 7.3 <0.001 
Permanent 
pacemakers post-
TAVI, % 
2.6 11.5 9.6 <0.001 
Prior aortic 
valvuloplasty, % 
4.2 2.2 2.6 <0.001 
Length of stay post-
TAVI (mean+SE, 
days) 
2.6+ 0.01 7.7+0.07 6.6+0.06 <0.001 
Hospital charges 
(mean+SE, $) 
157,663+ 2,062 208,752+ 1,581 197,895+ 1,343 <0.001 
Disposition, %    <0.001 
Home 84.7 59.3 64.7  
Extended care 
facility 
14.4 39.5 34.1  
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TIA: Transient ischemic attack; AKI: Acute kidney injury; ECMO: Extracorporeal membrane oxygenation; TAVI: 
Transcatheter aortic valve implantation 
 
 
 
 
 
 
Table 3: Multivariate Predictors of Early Discharge after TAVI 
 
 Adjusted Odds 
Ratio# 
95% Confidence 
Interval 
P value 
 Female 0.61 0.44-0.83 0.002 
Postoperative bleeding 0.36 0.18-0.72 0.004 
Blood transfusion 0.29 0.19-0.46 <0.001 
Stroke/TIA 0.13 0.02-0.94 0.04 
AKI 0.59 0.38-0.96 0.04 
Permanent pacemaker implantation 0.18 0.08-0.40 <0.001 
Mechanical circulatory support 0.31 0.13-0.75 0.009 
Year* 1.37 1.12-1.67 0.002 
Transfemoral TAVI approach@ 4.80 2.51-9.17 <0.001 
Prior aortic valvuloplasty 2.40 1.00-5.87 0.04 
#Model adjusted for baseline demographic variables: age, race; hospital level characteristics; Elixhauser comorbidity 
score; primary expected payer; median household income 
*Year 2012 vs. 2011;   @Transfemoral TAVI approach vs. Transapical TAVI approach 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Bar diagram of day of discharge after TAVI in entire cohort  
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Figure 1 Figure 2: Bar diagram of discharge destination stratified according to discharge timing 
 
 
Figure 2 Figure 3: Bar diagram of discharge timing stratified according to year of procedure 
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Figure 3 Figure 4: Bar diagram of discharge timing stratified according to TAVI approach 
 
 
 
Figure 4 Figure 5: Scatter plot diagram of costs of hospitalization vs. length of stay (day of 
discharge) after TAVI 
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FIGURE 5 
 
 
 
 
 
